Developing Diagnostic Nanobodies Against Aggregated TDP-43 Species
Developing Diagnostic Nanobodies Against Aggregated TDP-43 Species
批准号:
8517544
负责人:
MICHAEL R SIERKS
金额:
$18.27万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2015-07-31
关键词:
Alzheimer&aposs DiseaseAmyloid beta-ProteinAmyotrophic Lateral SclerosisAntibodiesAssesBindingBiological MarkersBiosensorBrainCellular StressDementiaDevelopmentDiagnosisDiagnosticDiagnostic testsDiseaseDisease ProgressionEventGoalsHumanHuntington DiseaseImmunoglobulin FragmentsLeadLewy Body DementiaMonitorMorphologyNeurodegenerative DisordersNeuronsParkinson DiseasePatientsProcessProteinsReagentSamplingSerumSpecificityStagingStructureTauopathiesTestingTherapeuticTissuesTraumatic Brain InjuryVariantalpha synucleinbasebrain tissuedirect applicationdisease diagnosisextracellularhuman Huntingtin proteinnanobodiesnew technologyprotein TDP-43protein aggregateprotein aggregationprotein misfoldingtau Proteinstherapeutic targettreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Protein misfolding and aggregation is a common thread behind many neurodegenerative diseases including Alzheimer's disease (AD), Lewy Body Dementia (LBD), and Parkinson's disease (PD) among others. While each disease has been primarily associated with aggregation of a specific protein; beta-amyloid (abeta) with AD, tau with AD and other tauopathies, alpha-synuclein (¿-syn) with PD and LBD, more than one protein is likely to misfold and aggregate in brain tissue complicating diagnosis and treatment strategies. Aggregation of another neuronal protein, TDP-43, has been strongly correlated with amyotrophic lateral sclerosis (ALS) and Frontal Temporal Dementia (FTD) and has also been associated with traumatic brain injury and AD among other neurodegenerative disorders. Since cellular stress induced by misfolding and aggregation of one protein such as abeta may well lead to misfolding and aggregation of other proteins such as ¿-syn, tau and TDP-43, the presence of multiple misfolded proteins in different diseases should be expected. Therefore characterizing which aggregated protein species are correlated with different stages of each disease would greatly facilitate development of better diagnostic and treatment strategies. We have generated several well characterized reagents that specifically recognize different aggregated species of abeta and ¿-syn, and have demonstrated that the reagents recognize aggregated species occurring in tissue from diseased brains, but not healthy brains, and that the reagents can have disease specificity as well. Here we will develop and test similar reagents for detecting specific forms of TDP-43 that are present in FTD and ALS brain tissue.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Novel atomic force microscopy based biopanning for isolation of morphology specific reagents against TDP-43 variants in amyotrophic lateral sclerosis.
基于新型原子力显微镜的生物淘选,用于分离针对肌萎缩侧索硬化症中 TDP-43 变体的形态特异性试剂。
DOI:
10.3791/52584
发表时间:
2015
期刊:
Journal of visualized experiments : JoVE
影响因子:
--
作者:
[Williams,StephanieM, Venkataraman,Lalitha, Tian,Huilai, Khan,Galam, Harris,BrentT, Sierks,MichaelR]
通讯作者:
Sierks,MichaelR
Isolation and characterization of antibody fragments selective for human FTD brain derived TDP-43 variants.
对人 FTD 脑源性 TDP-43 变体具有选择性的抗体片段的分离和表征。
DOI:
10.1186/s12868-020-00586-0
发表时间:
2020
期刊:
BMC neuroscience
影响因子:
2.4
作者:
[Venkataraman,Lalitha, He,Ping, Khan,Galam, Harris,BrentT, Sierks,MichaelR]
通讯作者:
Sierks,MichaelR
TDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis.
TDP-43蛋白变异作为肌萎缩性侧硬化症中的生物标志物。
DOI:
10.1186/s12868-017-0334-7
发表时间:
2017-01-25
期刊:
BMC neuroscience
影响因子:
2.4
作者:
[Williams SM, Khan G, Harris BT, Ravits J, Sierks MR]
通讯作者:
Sierks MR
Purification and Characterization of a toxic AD associated intracellularly generated amyloid beta fragment
-
批准号:10511148
-
项目类别:
-
资助金额:$43.18万
-
财政年份:2022
-
负责人:MICHAEL R SIERKS
-
依托单位:
Protein variants as blood based biomarkers for diagnosing and staging AD
-
批准号:9977069
-
项目类别:
-
资助金额:$34.96万
-
财政年份:2016
-
负责人:MICHAEL R SIERKS
-
依托单位:
Protein variants as blood based biomarkers for diagnosing and staging AD
-
批准号:9334047
-
项目类别:
-
资助金额:$34.96万
-
财政年份:2016
-
负责人:MICHAEL R SIERKS
-
依托单位:
Nanobodies selective for oligomeric Tau species isolated from AD brain
-
批准号:8633097
-
项目类别:
-
资助金额:$23.83万
-
财政年份:2013
-
负责人:MICHAEL R SIERKS
-
依托单位:
Nanobodies selective for oligomeric Tau species isolated from AD brain
-
批准号:8741902
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2013
-
负责人:MICHAEL R SIERKS
-
依托单位:
Developing Diagnostic Nanobodies Against Aggregated TDP-43 Species
-
批准号:8386058
-
项目类别:
-
资助金额:$24.55万
-
财政年份:2012
-
负责人:MICHAEL R SIERKS
-
依托单位:
Intracellular tools to study specific misfolded protein variants in human disease
-
批准号:8307797
-
项目类别:
-
资助金额:$15.34万
-
财政年份:2011
-
负责人:MICHAEL R SIERKS
-
依托单位:
Intracellular tools to study specific misfolded protein variants in human disease
-
批准号:8191309
-
项目类别:
-
资助金额:$18.19万
-
财政年份:2011
-
负责人:MICHAEL R SIERKS
-
依托单位:
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES
-
批准号:6092779
-
项目类别:
-
资助金额:$17.87万
-
财政年份:2000
-
负责人:MICHAEL R SIERKS
-
依托单位:
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES
-
批准号:6372479
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2000
-
负责人:MICHAEL R SIERKS
-
依托单位:
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES
-
批准号:6631468
-
项目类别:
-
资助金额:$25.6万
-
财政年份:2000
-
负责人:MICHAEL R SIERKS
-
依托单位:
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES
-
批准号:6509737
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2000
-
负责人:MICHAEL R SIERKS
-
依托单位:
INHIBITING AGGREGATION WITH PHAGE DISPLAY ANTIBODIES
-
批准号:6685537
-
项目类别:
-
资助金额:$4.39万
-
财政年份:2000
-
负责人:MICHAEL R SIERKS
-
依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
-
批准号:81000622
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:梁胜
-
依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
-
批准号:31060293
-
项目类别:地区科学基金项目
-
资助金额:26.0万元
-
批准年份:2010
-
负责人:郭亚芬
-
依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
-
批准号:30960334
-
项目类别:地区科学基金项目
-
资助金额:22.0万元
-
批准年份:2009
-
负责人:董贵成
-
依托单位: